Cardica
This article was originally published in The Gray Sheet
Executive Summary
Results of a 100-patient trial of Cardica's C-Port distal anastomosis system for cardiac bypass are presented by Michael Mack, MD, Cardiothoracic Surgery Associates of North Texas at the European Association for Cardiothoracic Surgery/European Society of Thoracic Surgeons joint meeting in Leipzig, Germany Sept. 13. Patency of bypass vessels attached with C-Port was 96.9% after six months, compared to 84.9% in historical studies. Cardica, which is 20% owned by Guidant, will use the data to support a CE mark and 510(k) indication in the coming months, the firm says...
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.